Loading
A phase 2/3 trial testing PF-08634404 in gastric & gastro-oesophageal junction cancer and oesophageal cancer, now recruiting.
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer is a phase 2/3 interventional study registered as NCT07392892, led by Pfizer, and recruiting on the registry. Official title: A phase 2/3 interventional study of PF-08634404 in combination with chemotherapy in treatment-naïve participants with locally advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma. Planned enrolment is 840 participants (estimated). The study started in 2026-05-14 and primary completion is expected in 2031-07-22. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/